FLT3 and acute myeloid leukemia: In intensively treated patients with newly diagnosed FLT3‐ITD‐mutated AML, Sasaki et al. demonstrated that adding sorafenib to induction chemotherapy improved the response rate to 98% compared to 83% in patients receiving chemotherapy alone (χ2 test, p = 0.057).